Dr Lindsay Fraser
Dr Lindsay Fraser has gained extensive knowledge in the field of regenerative medicine and cellular therapy by working across clinical, academic and commercial sectors including the Scottish National Blood Transfusion Service (SNBTS - islet isolation laboratory), Edinburgh University (PhD), Miltenyi Biotec and BioBest Laboratories Ltd. Her current role as a Cell Therapy Development (CTD) Manager for RoslinCT involves all aspects of cell therapy translation from streamlining research grade investigations to Good Manufacturing Practice (GMP) manufacture of cell therapies within a clean room facility. These processes are developed to provide autologous and allogeneic therapies to scale with concurrent development of cell characterisation assays and in line with current Medicines and Healthcare Products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA) regulations to ensure patient safety.
Her previous employment with the SNBTS involved the procurement and handling of cellular and tissue product (human biology and anatomy) for human transplant. This included product processing, issue, dispatch and reinfusion of tissues and cell products to patients in accordance with MHRA, Human Tissue Authority (HTA) and Human Fertilisation and Embryology Authority (HFEA) regulations.